Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
Clinical trial NCT05027074 · COMPLETED
Trial details
- NCT number
- NCT05027074
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-17
- Primary completion
- 2024-10-30
- Enrollment
- 506
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.